Qatar University (QU) has achieved a significant milestone in diabetes treatment research, uncovering a groundbreaking discovery with immense promise for individuals living with diabetes, particularly Type 2.
Led by Dr. Layla al-Mansoori, the QU Biomedical Research Centre (BRC) research team focused on the critical role of the protein GATA3 in the development of this chronic health condition.
“Our findings provide a solid foundation for further investigations into the potential benefits of inhibiting GATA3,” said Dr. Layla al-Mansoori, QU Biomedical Research Centre.
The researchers utilized a GATA3-specific DNAzyme encapsulated in liposome particles, leading to exciting findings that showed in-vitro GATA3 inhibition induced adipogenesis in primary human pre-adipocytes and enhanced insulin signaling in an insulin-resistant in-vitro model.
“This discovery represents a promising approach to diabetes treatment, with the potential to transform lives and improve patient outcomes,” Dr. Layla al-Mansoori added.
Moreover, in-vivo GATA3 inhibition not only promoted adipogenesis at the injection site but also led to a reduction in omental tissue size, indicating potential therapeutic benefits for correcting impaired adipogenesis and improving insulin sensitivity.
The research, patented at the United States Patent and Trademark Office in December 2021, has attracted attention from international pharmaceutical companies.
The office of Strategic Innovation, Entrepreneurship, and Economic Development at QU, along with the inventors, is actively exploring potential investments.
“While further research is necessary to fully comprehend the effects of GATA3 inhibition and determine its therapeutic efficacy for individuals with diabetes, our findings provide a solid foundation for further investigations into the potential benefits of inhibiting GATA3,” Dr. al-Mansoori emphasized.
This groundbreaking discovery offers hope for improved diabetes treatment and opens new possibilities in the fight against this chronic health condition.
Source: Gulf Times